Sergey Terushkin, MD, FACS As a bariatric surgeon and weight-loss specialist, Ive watched the evolution of obesity treatment for over a decade
Nausea is the most commonly reported symptom with both treatments, particularly during the dose-escalation phase
Patients should monitor for: Unexpected blood glucose elevations without clear cause (dietary changes, illness, new medications) Recurrence of diabetes symptoms such as increased thirst, urination, or fatigue Persistent high blood glucose readings (300 mg/dL) or symptoms of diabetic ketoacidosis (nausea, vomiting, abdominal pain, fruity breath) Severe abdominal pain (possible pancreatitis) These clinical changes have multiple potential causes beyond medication potency loss
With Musk earning the moniker Ozempic Santa, discussions around the widespread use of GLP-1 inhibitors similar to Ozempic and Wegovy are heating up
Animal studies also tout promising results with acetyl-L-carnitine supplementation